Bristol Myers Squibb, RayzeBio, RYZ101, Actinium-225, 225Ac-DOTATATE, ACTION-1 Trial, Phase 3 Clinical Trial, GEP-NETs, Neuroendocrine Tumors,

PRINCETON, New Jersey — October 12, 2026 Bristol Myers Squibb announced positive topline results from the planned interim analysis...